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Background: We compared the sensitivity and specificity of liquid-based cytology (LBC) and computer-assisted reading for
SurePath/FocalPoint and ThinPrep with those of manually read conventional cytology in routine cervical screening in four Danish
laboratories.
Methods: Using data from five nationwide registers, technological phases were identified by slide preparation, reading technique,
and triage of borderline cytology. Trends in the detection of cervical intraepithelial neoplasia (CIN) were an indicator of the
technology’s relative sensitivity, and trends in false-positive tests an indicator of relative specificity.
Results: At 23–29 years, SurePath/FocalPoint statistically significantly increased the detection of XCIN3 by 85% compared with
manually read conventional cytology. The 11% increase with ThinPrep was not significant. At 30–44 years, the increase with
SurePath/FocalPoint was 58%; the 16% increase with ThinPrep was not significant. At 45–59 years, both technologies led to
nonsignificant decreases in the detection. SurePath/FocalPoint doubled the frequency of false-positive tests at any age. With
ThinPrep, these proportions remained the same at 23–29 years, but decreased by two-thirds at 45–59 years. In a fourth laboratory
with continuous use of manually read conventional cytology, no such trends were seen.
Conclusions: The sensitivity and specificity of modern LBC and computer-assisted reading technologies may be brand- and age-
dependent.
In the past two decades, the classical Pap smear has been replaced
by liquid-based cytology (LBC), whereas manual reading is now
assisted by computer reading. At present, the cytology market is
dominated by ThinPrep (Hologic, Bedford, MA, USA) and
SurePath/FocalPoint (BD, Franklin Lakes, NJ, USA) technologies.
The advantages of LBC include purified stains, cell monolayers,
and the ability to run additional analyses on the same sample,
for example, for human papillomavirus (HPV) or biomarker
expression testing. Computer-assisted reading systems deselect
normal samples and point cytologists to the most critical areas in
suspect samples.
The use of the new technologies has also affected women. In two
routine Danish laboratories, the switch to SurePath LBC
significantly increased the proportions of abnormal cytological
samples at age o45 years, and decreased them in older women
(Barken et al, 2014; Rask et al, 2014). ThinPrep LBC in another
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Danish laboratory was associated with a decreased proportion of
abnormal cytological samples at any age. This decrease was
especially large around menopause, possibly because LBC makes
neoplastic lesions more easily distinguished from, for example,
atrophy. Computer-assisted reading technologies increased the
proportions of abnormal cytology regardless of the brand and the
woman’s age.
These changes led to a different selection of women referred for
further follow-up. The next question is, therefore, whether there
was also a change in the detection of high-grade cervical
intraepithelial neoplasia (CIN). Previous trials comparing LBC
and/or computer-assisted reading to conventional methods led to
conflicting results regarding the changed CIN detection; some
suggested a statistically significantly decreased, some equal, and
some a significantly increased detection (Arbyn et al, 2008;
Kitchener et al, 2011a; Klug et al, 2013).
Based on routine screening data from four laboratories
evaluating about one-third of all cytology in Denmark, we aimed
to determine whether the age-specific changes in abnormal
cytology described above led to changes in the detection of
histologically confirmed high-grade CIN.
MATERIALS AND METHODS
Cervical screening has been undertaken in Denmark since the
1960s. In 1986, organised cytological screening at age 23–59 years
was recommended every 3 years. Since 2007, women aged 50–65
years have been targeted every 5 years, whereas since 2012, women
agedX60 years can be ‘checked out’ of the programme following a
negative HPV test result. Screening coverage has been around 75%,
with negligible regional variation.
Previously, we studied changes in the detection of atypical
squamous cells of undetermined significance or worse (XASCUS)
following the introduction of LBC and computer-assisted reading
technologies in 1998–2007 in Departments of Pathology of
Copenhagen University Hospital Hvidovre, Hillerød Hospital,
and Odense University Hospital (Table 1) (Barken et al, 2013; Rask
et al, 2014). Department of Pathology of Roskilde County Hospital,
retaining manually read conventional cytology, was used to study
technology-independent changes, for example, changes in the
background risk of cervical cancer. Each laboratory served well-
defined catchment areas: Hvidovre laboratory received samples
from Copenhagen and Frederiksberg Municipalities; Hillerød from
Frederiksborg County; Roskilde from Roskilde County; and
Odense from Funen County. The coverage rates of the target
population were stable, as was the case-mix of samples (screening
vs follow-up).
Data sources. We retrieved the information on the women’s age
and place of residence from the Danish Civil Registration System.
Since 1968, every resident has been registered with a unique
identification number (CPR number). Data on cervical cytology
and biopsies including their diagnoses were obtained from the
Pathology Data Bank (Patobank). We also retrieved data on
conisations from the Patobank; since mid-1990s, conisations were
most frequently undertaken as large loop excisions of the
transformation zone and had a specific Danish Systematised
Nomenclature of Medicine (SNOMED) code. Additional data on
cervical treatments including conisations, destructive therapies,
hysterectomies, excisions, and other less frequent types of
treatment (Barken et al, 2012) were retrieved from (a) the National
Patient Register where information on in-patient treatments and
the associated diagnoses has been available since 1978, and on out-
patient treatments since 1995, and from (b) the National Health
Service Register containing non-diagnostic information on biopsies
and cervical treatments undertaken by private gynaecologists since
1990. The Danish Cancer Register was used to obtain information
on incident cervical cancers since 1943. Data were retrieved from
the beginning of the registration until end of 2010 and were linked
using the CPR number.
In the Patobank, diagnoses were registered using the SNOMED
classification. Diagnoses were classified into Bethesda 2001
categories. An exception was made for Hvidovre (Barken et al,
2014), where samples from women aged X30 years with an initial
ASCUS diagnosis and a negative reflex HPV test were, during a
limited time period, routinely downgraded to normal cytology. As
these women were recommended for repeated testing despite the
nominally normal diagnosis, we reclassified them as having
ASCUS.
Technology phases. Laboratories were autonomous in making
decisions regarding the technology and the combinations of slide
preparation and reading technologies differed even between the
laboratories that used the same brand. Consequently, data were
analysed for each laboratory separately.
As described previously (Barken et al, 2013; Rask et al, 2014),
technological phases were identified by slide preparation, reading
technique, and triage of ASCUS at X30 years. All piloting and
implementation periods were excluded. ‘Baseline’ in phase 1 was
defined for all laboratories as manual reading of conventional
cytology with cytological triage of ASCUS. The Odense laboratory
returned to manually read conventional cytology after a ThinPrep
LBC pilot. Because the differences in the proportions of all studied
end points were not statistically significant, data for pre- and
postpilot periods were merged (excluding the pilot).
In phase 2, Hvidovre laboratory started using FocalPoint
reading technology. FocalPoint Slide Profiler replaced manual
reading, and the cutoff for no further review of normal samples
was set to 50% following an internal pilot. The remaining samples
were automatically divided into five quintiles of likelihood of
abnormalities. In phase 3, SurePath LBC replaced conventional
cytology, whereas the laboratory continued using FocalPoint Slide
Profiler with a 50% cutoff. This cutoff was changed to the
manufacturer’s recommended 25% in phase 4, meaning that
cytotechnicians and pathologists had to evaluate 75% instead of
50% of all samples. Additionally, cytology was replaced by HPV
testing in triage of ASCUS at ageX30 years using Qiagen’s Hybrid
Capture 2 (HC2) assay. In phase 5, FocalPoint GS Imaging System
was added, which, in the 75% of samples not automatically signed
out by the FocalPoint Slide Profiler, guided the cytotechnicians
through 16 preselected fields of view (most likely to contain
abnormalities).
Hillerød laboratory closely followed the changes made in
Hvidovre. In phase 2, it introduced FocalPoint Slide Profiler with
the 50% cutoff, which was changed to 25% in phase 3 together with
introducing SurePath LBC. In phase 4, FocalPoint GS Imaging
System was added. Throughout the study period, ASCUS was
triaged with cytology.
Odense laboratory started using ThinPrep technology in phase 2
when conventional cytology was replaced by LBC using ThinPrep
Pap test in T3000 processor (Hologic). In phase 3, ThinPrep
Imaging System (Hologic) including Imaging Pap Stain replaced
conventional Pap stain and manual reading. The system guided the
cytotechnician to 22 fields of view. Also here, cytology was used to
triage ASCUS in all phases.
To determine potential trends in Roskilde, manually read
conventional cytology data were analysed in arbitrary 3-year
periods.
Inclusion criteria. We included samples taken from 1 January
1998 to 31 December 2007 at age 23–59 years, the target age until
2007. As an exception, we excluded year 2007 for Hillerød and
Roskilde since a national administrative reorganisation led to
changes in their catchment areas. Samples taken for follow-up of
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recent abnormalities were excluded. Previous analyses (Barken
et al, 2013; Rask et al, 2014) used the same definitions.
The worst histological outcome was determined within 2.5 years
after the abnormal cytological sample. Women who died or
emigrated from Denmark during the follow-up were excluded.
Some biopsies were evaluated by private pathologists who were
historically not obliged to report their diagnostic data to the
Patobank. Women were, therefore, also excluded if they lived in, or
moved to, a county with inadequate histological registration in
the Patobank, defined as registration of o85% of all biopsies
(Barken et al, 2012). This implies exclusion of samples from
Hillerød before 1 January 2003, and from Hvidovre/Frederiksberg
before 1 January 2001.
Samples taken for follow-up of recent abnormalities were those
with a preceding cervical cancer diagnosis; CIN diagnosis or
treatment in p10 years; high-grade cervical squamous intrae-
pithelial lesions or worse (XHSIL), inadequate cytology, or a
positive HPV test result in the past 12 months; and inadequate/
negative histology, low-grade cervical intraepithelial lesions, or
ASCUS in the past 15 months. The remaining were predominantly
screening samples, taken either in organised or opportunistic
settings. As the indication for sample taking was not registered,
they may have also contained a small proportion of samples taken
for investigation of symptoms. The proportion of the latter
samples was assumed not to be associated with the technological
phases.
Statistical analysis. ASCUS was the cutoff for abnormal cytology
as it was the indication for further follow-up. The following end
points were determined per 100 screening samples: detection of
histologically confirmed CIN2 and XCIN3, number of CIN
treatments (all indicators of cytology’s sensitivity), detection of
histologically confirmed oCIN2, and number of false-positive
samples (indicators of specificity). False-positive samples were
defined asXASCUS withoutXCIN2 orXCIN3 during follow-up
(Rebolj et al, 2012). Cervical intraepithelial neoplasia treatments
included all conisations (most frequently undertaken as large-loop
excision of the transformation zone), and destructive therapies,
hysterectomies, excisions, and other less frequent treatments if
histological CIN of any grade was registered in the period between
Table 1. Description of phases by laboratory
Laboratory
(county catchment area)
and phase Period Slide preparation Reading technique Triage
Roskilde (Roskilde County)
Phase 1 1 January 1998 to
31 December 2000
Conventional cytology Manual Cytology
Phase 2 1 January 2001 to
31 December 2003
As above As above As above
Phase 3 1 January 2004 to
31 December 2006
As above As above As above
Hvidovre (Copenhagen and Frederiksberg Municipalities)a
Phase 1 1 January 1998 to
30 September 1999
Conventional cytology Manual Cytology
Phase 2 1 July 2000 to
30 April 2002
As above Computer-assisted (BD FocalPoint Slide
Profiler, 50% cutoff)
As above
Phase 3 1 August 2002 to
30 April 2005
LBC (SurePath Pap test, BD
PrepStain Slide Processor)
As above As above
Phase 4 1 October 2005 to
30 November 2006
As above Computer-assisted (BD FocalPoint Slide
Profiler, 25% cutoff)
HPV DNA (Qiagen
Hybrid Capture 2)b
Phase 5 1 April 2007 to
31 December 2007
As above Computer-assisted (as above plus BD
FocalPoint GS Imaging System)
As above
Hillerød (Frederiksborg County)c
Phase 1 1 January 1998 to
31 July 2002
Conventional cytology Manual Cytology
Phase 2 1 September 2002 to
31 December 2003
As above Computer-assisted (BD FocalPoint Slide
Profiler, 50% cutoff)
As above
Phase 3 1 October 2004 to
31 October 2005
LBC (BD SurePath Pap test,
BD PrepStain Slide processor)
Computer-assisted (BD FocalPoint Slide
Profiler, 25% cutoff)
As above
Phase 4 1 February 2006 to
31 October 2006
As above Computer-assisted (as above plus BD
FocalPoint GS Imaging System)
As above
Odense (Funen County)
Phase 1a 1 January 1998 to
31 December 1998
Conventional cytology Manual Cytology
Phase 1b 1 November 1999 to
31 May 2001
As above As above As above
Phase 2 1 January 2004 to
30 September 2004
LBC (Hologic ThinPrep Pap test,
T3000 Slide Processor)
As above As above
Phase 3 1 October 2006 to
31 December 2007
As above Computer-assisted (Hologic ThinPrep
Imaging System)
As above
Abbreviations: ASCUS¼ atypical squamous cells of undetermined significance; HPV¼ human papillomavirus; LBC¼ liquid-based cytology. Note: All periods between phases represented
periods of piloting and implementation of the technology, and were excluded from the study.
aOwing to incomplete histological registration before 2001 for women residing in Frederiksberg Municipality, data were analysed separately by municipality (from phase 1 onwards for women
residing in Copenhagen Municipality, and for Frederiksberg Municipality only from phase 2 onwards).
bThis also signifies a change in the recommended follow-up. Whereas with cytological triage, all women with ASCUS were recommended for repeated testing at 6/12 months, they were
recommended for immediate colposcopy if HPV-positive, and for repeated testing in 12 months if HPV-negative.
cOwing to incomplete histological registration for women residing in Frederiksborg County, only data for samples taken from 1 January 2003 onwards were included in the analysis, that is, from
phase 2 onwards.
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3 months before and 1 month after the treatment (Barken et al,
2012). We calculated the positive predictive value (PPV) for
XCIN2 and XCIN3 as the number of detected lesions per 100
screening samples with an XASCUS diagnosis.
The main comparison was between manually read conven-
tional cytology (baseline/phase 1) and full implementation of
modern cytological technologies by end of 2007 (the last phase
per laboratory). Per laboratory, we calculated relative propor-
tions (RPs) of the observed end points in the final phase
compared with the baseline. The data for the baseline situation
were not available for Hvidovre/Frederiksberg and Hillerød, thus
these laboratories did not contribute here. To assess the
contribution of each change in technology, we also calculated
RP comparing with the previous phase. We stratified the
comparisons by age group (23–29, 30–44, and 45–59 years).
The 95% confidence intervals (CI) for RP were calculated
assuming log-normal distribution.
Proportions of XASCUS were a focus of previous publications
(Barken et al, 2014; Rask et al, 2014), and were not further
discussed here. Because for the present analysis the definition of
the at-risk population excluded women whose histological out-
comes could not be reliably determined, these proportions were
tabulated anew. The proportions of women with XASCUS with
and without the exclusion were similar.
RESULTS
Study population. In total, 674 248 samples were included:
151 135 from Roskilde, 283 310 from Hvidovre/Copenhagen,
38 831 from Hvidovre/Frederiksberg, 71 915 from Hillerød, and
129 057 from Odense (Table 2). Relatively few samples from
counties with incomplete histological registration were excluded
(Table A1), most often from Hvidovre serving the area with
traditionally highest rates of migration to other counties. The age
distribution and completeness of routine follow-up did not change
substantially between phases in each laboratory. Most abnormal
samples (X90%) had follow-up. The Roskilde, Odense, and
Hillerød laboratories served a population with a higher average
age than Hvidovre (Table A2).
Changes in the laboratory with continuous use of manually read
conventional cytology. In Roskilde, few changes between the last
and the first phase were observed (Table 3 and Figure 1: detection
of XCIN2; Figure 2: detection of oCIN2; and Figure 3: false-
positive tests). The changes were only significant for the
proportions of false-positive tests and oCIN2 biopsies, particu-
larly at 45–59 years. A more detailed phase-by-phase comparison
by age revealed some fluctuations but no trends (Table A3).
Changes with SurePath technologies. In Hvidovre/Copenhagen,
full implementation of SurePath/FocalPoint LBC and reading
technologies compared with manually read conventional cytology
was associated with a doubling of the frequency of all studied
outcomes at 23–44 years, with the exception of a decreased PPV
for XCIN2/XCIN3. In older women, 45–59 years, the only
statistically significant change was a doubling of the frequency of
false-positive tests, and a corresponding decrease in the PPV.
The first step toward computer-assisted reading using a 50%
cutoff on FocalPoint Slide Profiler (comparing phase 2 with phase 1,
using conventional cytology and cytological triage of ASCUS in
both phases) had little impact on the studied outcomes (Table A4).
At 23–29 years, however, the frequency of oCIN2 biopsies and
false-positive tests increased significantly by 10–30%. At 45–59
years, detection of XCIN3 statistically significantly decreased (by
36%). The overall PPV for XCIN2/XCIN3 decreased by 13%.
SurePath LBC implementation (comparing phase 3 with phase 2,
using FocalPoint Slide Profiler for reading with a 50% cutoff and
cytological triage of ASCUS in both phases) was associated with a
statistically significantly increased detection ofoCIN2, high-grade
CIN, and the frequency of CIN treatments at 23–29 years, all by
30–40%, and in the frequency of false-positive tests by450%. The
increases were slightly smaller at 30–44 years. In women around
menopause, 45–59 years, the decreases in CIN detection and in
false-positive tests after the introduction of LBC were generally not
statistically significant.
After a change in the FocalPoint Slide Profiler’s cutoff from 50
to 25%, and a concurrent introduction of HPV triage for ASCUS
(comparing phase 4 to phase 3 using SurePath LBC in both
phases), statistically significant increases in all studied outcomes
were observed at 23–44 years (by Bþ 20–30%). At 45–59 years,
significantly increased frequency was observed foroCIN2 biopsies
(þ 23%), XCIN3 (þ 66%), and false-positive tests (þ 73%).
The addition of FocalPoint GS Imaging System (comparing
phase 5 with phase 4, using FocalPoint Slide Profiler with a 25%
cutoff, SurePath LBC, and HC2 triage of ASCUS in both phases)
was associated with statistically insignificant increases in the
frequency of most studied outcomes. However, at 30–59 years, the
frequency of false-positive tests increased significantly (by
Bþ 20%), and so did the frequency of oCIN2 biopsies at 23–
44 years (þ 25–30%).
Similar patterns in the RP of the studied outcomes across phases
were seen also at Hvidovre/Frederiksberg (Table A5) and Hillerød
(Table A6).
Changes with ThinPrep technologies. After full implementation
of ThinPrep LBC and reading technologies in Odense, the
detection of CIN2 and the frequency of CIN treatments statistically
significantly increased at 23–29 years, by 77 and 22%, respectively.
Among older women, the decreases in the frequency of oCIN2
biopsies ( 29% at 30–44 years and  61% at 45–59 years) and of
false-positive tests ( 36% at 30–44 years and  65% at 45–59
years) were statistically significant (Table 3). Correspondingly, the
overall PPV increased by 51% (forXCIN2) and 41% (forXCIN3);
at age 45–59 years, the increase was particularly high, 105% for
XCIN2.
ThinPrep LBC implementation (comparing phase 2 with phase 1,
using manual reading in both phases) was associated with a
statistically significant decrease in the frequency of false-positive
tests at all ages ( 18% at 23–29 years,  53% at 30–44 years, and
 76% at 45–59 years; Table A7). The frequency of oCIN2
biopsies also decreased ( 41% at 30–44 years and  69% at
45–59 years). There was a tendency toward a decreased detection
of CIN2 and a slightly increased detection of XCIN3 in all three
age groups, although these changes were not statistically
significant. The PPV increased particularly at 30–44 years (by
83% for XCIN3) and at 45–59 years (by 302% for XCIN3).
With ThinPrep Imaging System (comparing phase 3 with phase
2, using ThinPrep LBC in both phases), the detection of CIN2 at
23–29 years increased significantly (þ 135%), and detection of
XCIN3 at 45–59 years decreased ( 53%). Also, the frequency of
false-positive tests increased, by 34% at 30–44 years, and by 45% at
45–59 years. Consequently, the PPV decreased, by 24% (for
XCIN3) at 23–29 years, and by 63% (for XCIN3) at 45–59 years.
DISCUSSION
General findings. In the Danish routine screening data, cytology
using SurePath LBC and FocalPoint computer-assisted reading
technologies (with possibly also an intervening effect of HPV
triage) appeared to be more sensitive for the detection of high-
grade CIN but less specific compared with manually read
conventional cytology, predominantly at younger ages. ThinPrep
LBC, on the other hand, decreased the sensitivity toward CIN2, but
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Table 2. Primary cytology samples and histological outcomes after 2.5-year follow-upa
Phase 1 Phase 2 Phase 3 Phase 4 Phase 5
Unchanged technology: Roskilde Baseline:
Conventional
cytology, manual
reading, cytology
triage of ASCUS
(N¼ 53 979)
Conventional
cytology, manual
reading, cytology
triage of ASCUS
(N¼49 856)
Conventional
cytology, manual
reading, cytology
triage of ASCUS
(N¼ 47 300)
Not relevant Not relevant
XASCUS 1173 (2%) 1251 (3%) 1012 (2%) — —
CIN2 118 (0.22%) 104 (0.21%) 85 (0.18%) — —
XCIN3 281 (0.52%) 289 (0.58%) 271 (0.57%) — —
CIN treatments 482 (0.9%) 491 (1.0%) 405 (0.9%) — —
oCIN2 471 (0.87%) 439 (0.88%) 323 (0.68%) — —
False positive for XCIN2 774 (1.4%) 858 (1.7%) 656 (1.4%) — —
False positive for XCIN3 892 (1.7%) 962 (1.9%) 741 (1.6%) — —
PPV for XCIN2 34% 31% 35% — —
PPV for XCIN3 24% 23% 27% — —
SurePath technology: Hvidovre
(Copenhagen)
Baseline:
Conventional
cytology, manual
reading, cytology
triage of ASCUS
(N¼ 62 644)
Conventional
cytology, FocalPoint
Slide Profiler 50%
cutoff, cytology
triage of ASCUS
(N¼59 274)
SurePath LBC,
FocalPoint Slide
Profiler 50% cutoff,
cytology triage of
ASCUS
(N¼ 94 541)
SurePath LBC, FocalPoint
Slide Profiler 25% cutoff,
HC2 triage of ASCUS
(N¼ 43 002)
SurePath LBC,
FocalPoint Slide Profiler
25% cutoffþ FocalPoint
Imaging System, HC2
triage of ASCUS
(N¼23 849)
XASCUS 2299 (4%) 2307 (4%) 4832 (5%) 2751 (6%) 1742 (7%)
CIN2 230 (0.37%) 201 (0.34%) 423 (0.45%) 242 (0.56%) 162 (0.68%)
XCIN3 624 (1.00%) 547 (0.92%) 1148 (1.21%) 641 (1.49%) 394 (1.65%)
CIN treatments 857 (1.4%) 828 (1.4%) 1780 (1.9%) 959 (2.2%) 603 (2.5%)
oCIN2 722 (1.15%) 801 (1.35%) 1414 (1.50%) 844 (1.96%) 581 (2.44%)
False positive for XCIN2 1445 (2.3%) 1559 (2.6%) 3261 (3.4%) 1868 (4.3%) 1186 (5.0%)
False positive for XCIN3 1675 (2.7%) 1760 (3.0%) 3684 (3.9%) 2110 (4.9%) 1348 (5.7%)
PPV for XCIN2 37% 32% 33% 32% 32%
PPV for XCIN3 27% 24% 24% 23% 23%
SurePath technology: Hvidovre
(Frederiksberg)
Baseline: As above
(excluded)
As above (N¼ 9385) As above
(N¼ 17 634)
As above (N¼ 7018) As above (N¼ 4794)
XASCUS — 361 (4%) 830 (5%) 420 (6%) 352 (7%)
CIN2 — 26 (0.28%) 77 (0.44%) 51 (0.73%) 39 (0.81%)
XCIN3 — 97 (1.03%) 195 (1.11%) 107 (1.52%) 80 (1.67%)
CIN treatments — 134 (1.4%) 304 (1.7%) 169 (2.4%) 140 (2.9%)
oCIN2 — 113 (1.20%) 239 (1.36%) 105 (1.50%) 122 (2.54%)
False positive for XCIN2 — 238 (2.5%) 558 (3.2%) 262 (3.7%) 233 (4.9%)
False positive for XCIN3 — 264 (2.8%) 635 (3.6%) 313 (4.5%) 272 (5.7%)
PPV for XCIN2 — 34% 33% 38% 34%
PPV for XCIN3 — 27% 23% 25% 23%
SurePath technology: Hillerød Baseline:
Conventional
cytology, manual
reading, cytology
triage of ASCUS
(excluded)
Conventional
cytology, FocalPoint
Slide Profiler 50%
cutoff, cytology
triage of ASCUS
(N¼28 888)
SurePath LBC,
FocalPoint Slide
Profiler 25% cutoff,
cytology triage of
ASCUS
(N¼ 24 593)
SurePath LBC, FocalPoint
Slide Profiler 25%
cutoffþFocalPoint
Imaging System, cytology
triage of ASCUS
(N¼ 18 434)
Not relevant
XASCUS — 878 (3%) 865 (4%) 843 (5%) —
CIN2 — 67 (0.23%) 71 (0.29%) 77 (0.42%) —
XCIN3 — 151 (0.52%) 183 (0.74%) 181 (0.98%) —
CIN treatments — 281 (1.0%) 291 (1.2%) 280 (1.5%) —
oCIN2 — 318 (1.10%) 298 (1.21%) 275 (1.49%) —
False positive for XCIN2 — 660 (2.3%) 611 (2.5%) 585 (3.2%) —
False positive for XCIN3 — 727 (2.5%) 682 (2.8%) 662 (3.6%) —
PPV for XCIN2 — 25% 29% 31% —
PPV for XCIN3 — 17% 21% 21% —
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with higher specificity compared with conventional cytology,
particularly at older ages. ThinPrep computer-assisted reading
technologies were associated with a decrease in the specificity
compared with manual reading, but generally without correspond-
ing increases in high-grade CIN detection other than of CIN2 in
young women.
Comparison with the literature. In particular, the early literature
on new cytological technologies was dominated by studies in the
so-called ‘referral populations’. These women represented selected
subgroups of the screening population (Rebolj et al, 2014a),
identified as eligible after presenting with abnormal conventional
cytology. Hence, unlike in our study, lesions detectable using LBC
but less likely to be seen on conventional cytology would not be
considered. This might be one of the reasons why an influential
meta-analysis from 2008 concluded that LBC is as sensitive for
detection of XCIN2 as conventional cytology, relative sensitivity
1.03 (95% CI: 0.97–1.09) (Arbyn et al, 2008).
The LBC literature on primary screening has been dominated by
ThinPrep studies, but those led to widely differing results. In a
small French screening study (n¼ 1757), in which all women
underwent colposcopy, the sensitivity of ThinPrep LBC was 66%
(95% CI: 56–75), slightly but significantly (Po0.05) lower
compared with that of conventional cytology, 72% (95% CI: 63–
80) (Coste et al, 2003). In that study, LBC slides were made from
the material remaining after the conventional slides had been
prepared. Consistent with our data, two large randomised
controlled trials, from the Netherlands (n¼ 89 784) and Italy
(n¼ 45 174), observed the same detection of high-grade CIN with
ThinPrep LBC and conventional cytology (Ronco et al, 2007;
Siebers et al, 2009). However, in a smaller Swedish trial
(n¼ 13 484) ThinPrep LBC detected 62% (95% CI: 22–116) more
high-grade CIN compared with conventional cytology (Strander
et al, 2007). Also in a German trial comparing ThinPrep LBC with
conventional cytology atX20 years (n¼ 20 935) (Klug et al, 2013),
ThinPrep LBC detected substantially moreXCIN2 compared with
conventional cytology, RR: 2.40 (95% CI: 1.49–3.87). Although
other factors probably also had a role, the sensitivity of
conventional cytology might have differed across these studies.
Reading of conventional cytology tended to rely on internal
training, potentially allowing for interlaboratory variation. For
patented LBC technologies, the training and certification is the
manufacturer’s responsibility, and the clinical outcomes thereof
might be more uniform across laboratories.
A dearth of SurePath LBC studies with histological confirmation
of CIN created a void in the literature, thus our findings of an
increased sensitivity at younger ages could not be adequately
compared. There are three major differences between ThinPrep
and SurePath LBC that may have contributed to the observed
variation in CIN detection. First, ThinPrep contains methanol,
whereas SurePath contains formaldehyde and ethanol, leading to a
different morphology presentation on the final microscopy slide.
Second, SurePath cell material is first cleaned up for mucus and
debris on a column. ThinPrep is processed directly out of the vial;
samples are aspirated through a filter and dispensed onto the slide,
which potentially leaves cell material in the filter. Finally, for a
ThinPrep sample, the brush is rinsed in the liquid and afterwards
discarded by the smear taker, whereas the brush head is left in
SurePath until the cell material is transferred to the preprocessing
column before sedimentation on the cytology slide in the
laboratory. Taken together with the different vial sizes (20ml for
ThinPrep and 10ml for SurePath), this may potentially yield
differences in the available cellularity (Bigras et al, 2003; Umana
et al, 2013).
There have been few large evaluations of computer-assisted
reading technology with a histological reference. Most notably, the
large UK randomised controlled trial MAVARIC (n¼ 73 266)
compared ThinPrep and FocalPoint imaging-assisted reading with
manual reading in predominantly primary screening samples
(Kitchener et al, 2011b). Samples from some non-randomised
practices and from colposcopy clinics were included to raise the
number of abnormal samples. Unlike in our study, both ThinPrep
and FocalPoint were inferior in detecting high-grade CIN;
compared with manual reading, the relative sensitivity forXCIN2
was 0.92 (95% CI: 0.87–0.98) for ThinPrep and 0.90 (95% CI: 0.85–
0.96) for FocalPoint. In the German trial, the addition of
computer-assisted reading to LBC slightly increased the relative
detection of XCIN2 compared with manually read conventional
cytology, from 2.40 (with ThinPrep LBC alone, see above) to 2.70
(95% CI: 1.69–4.31; for ThinPrep LBCþ computer-assisted read-
ing). Also in two large Australian screening laboratories, ThinPrep
LBC combined with Imaging missed fewer high-grade CIN
compared with manually read conventional cytology (Davey
et al, 2007; Halford et al, 2010).
Table 2. ( Continued )
Phase 1 Phase 2 Phase 3 Phase 4 Phase 5
ThinPrep technologies: Odense Baseline:
Conventional
cytology, manual
reading, cytology
triage of ASCUS
(N¼ 74 522)
ThinPrep LBC,
manual reading,
cytology triage of
ASCUS (N¼ 20 921)
ThinPrep LBC,
ThinPrep Imaging
System, cytology
triage of ASCUS
(N¼ 33 614)
Not relevant Not relevant
XASCUS 3423 (5%) 536 (3%) 1087 (3%) — —
CIN2 183 (0.25%) 31 (0.15%) 106 (0.32%) — —
XCIN3 557 (0.75%) 163 (0.78%) 249 (0.74%) — —
CIN treatments 826 (1.1%) 219 (1.0%) 389 (1.2%) — —
oCIN2 1507 (2.02%) 215 (1.03%) 433 (1.29%) — —
False positive for XCIN2 1683 (3.6%) 342 (1.6%) 732 (2.2%) — —
False positive for XCIN3 2866 (3.8%) 373 (1.8%) 838 (2.5%) — —
PPV for XCIN2 22% 36% 33% — —
PPV for XCIN3 16% 30% 23% — —
Abbreviations: ASCUS¼ atypical squamous cells of undetermined significance; CI¼ confidence interval; CIN¼ cervical intraepithelial neoplasia; HC2¼ Hybrid Capture 2; LBC¼ liquid-based
cytology; PPV¼positive predictive value; RP¼ relative proportion; triage¼ in case of ASCUS at age X30 years. Bold signifies significant change comparing the current phase with the most
recent preceding phase, based on 95% CI for the calculated RP.
aIn women aged 23–59 years, by laboratory and phase.
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Table 3. Effect of full implementation of SurePath/FocalPoint or ThinPrep LBC and computer-assisted reading (last phase)a
No change (Roskilde)b SurePath (Hvidovre [CPH M])c ThinPrep (Odense)d
Before Baseline: Conventional cytology,
manual reading, cytology triage of
ASCUS
Baseline: conventional cytology, manual reading,
cytology triage of ASCUS
Baseline: Conventional cytology,
manual reading, cytology triage of
ASCUS
After As above SurePath LBC, FocalPoint Slide Profiler 25%
cutoffþFocalPoint Imaging System, HC2 triage of
ASCUS
ThinPrep LBC, ThinPrep Imaging
System, cytology triage of ASCUS
23–59 years 47300/53 979 23 849/62 644 33 614/74 522
XASCUS 1012/1173, 0.98 (0.91–1.07) 1742/2299, 1.99 (1.87–2.11) 1087/3423, 0.70 (0.66–0.75)
CIN2 85/118, 0.82 (0.62–1.09) 162/230, 1.85 (1.51–2.26) 106/183, 1.28 (1.01–1.63)
XCIN3 271/281, 1.10 (0.93–1.30) 394/624, 1.66 (1.46–1.88) 249/557, 0.99 (0.85–1.15)
CIN treatments 405/482, 0.96 (0.84–1.09) 603/857, 1.85 (1.67–2.05) 389/826, 1.04 (0.93–1.18)
oCIN2 323/471, 0.78 (0.68–0.90) 581/722, 2.11 (1.90–2.36) 433/1507; 0.64 (0.57–0.71)
False positive for XCIN2 656/774, 0.97 (0.87–1.07) 1186/1445, 2.16 (2.00–2.32) 732/2683, 0.60 (0.56–0.66)
False positive for XCIN3 741/892, 0.95 (0.86–1.04) 1348/1675, 2.11 (1.97–2.27) 838/2866, 0.65 (0.60–0.70)
PPV for XCIN2 35%/34%, 1.03 (0.92–1.16) 32%/37%, 0.86 (0.79–0.94) 33%/22%, 1.51 (1.36–1.68)
PPV for XCIN3 27%/24%, 1.12 (0.97–1.29) 23%/27%, 0.83 (0.75–0.93) 23%/16%, 1.41 (1.23–1.61)
23–29 years 5572/7350 8228/21 536 5310/14 299
XASCUS 215/273, 1.04 (0.87–1.24) 815/1020, 2.09 (1.91–2.28) 435/1066, 1.10 (0.99–1.22)
CIN2 22/38, 0.76 (0.45–1.29) 94/136, 1.81 (1.39–2.35) 61/93, 1.77 (1.28–2.44)
XCIN3 71/73, 1.28 (0.93–1.78) 204/288, 1.85 (1.55–2.21) 103/250, 1.11 (0.88–1.39)
CIN treatments 103/133, 1.02 (0.79–1.32) 326/411, 2.08 (1.80–2.40) 167/373, 1.21 (1.01–1.44)
oCIN2 49/91, 0.71 (0.50–1.00) 258/258, 2.62 (2.21–3.10) 142/372, 1.03 (0.85–1.24)
False positive for XCIN2 122/162, 0.99 (0.79–1.25) 517/596, 2.27 (2.02–2.55) 271/723, 1.01 (0.88–1.16)
False positive for XCIN3 144/200, 0.95 (0.77–1.17) 611/732, 2.18 (1.97–2.43) 332/816, 1.10 (0.97–1.24)
PPV for XCIN2 43%/41%, 1.06 (0.86–1.31) 37%/42%, 0.88 (0.78–0.99) 38%/32%, 1.17 (1.01–1.36)
PPV for XCIN3 33%/27%, 1.23 (0.94–1.62) 25%/28%, 0.89 (0.76–1.03) 24%/23%, 1.01 (0.83–1.23)
30–44 years 21827/23 376 10 081/24 753 14 370/32 819
XASCUS 544/548, 1.06 (0.95–1.20) 664/864, 1.89 (1.71–2.08) 472/1435, 0.75 (0.68–0.83)
CIN2 49/66, 0.80 (0.55–1.15) 62/84, 1.81 (1.31–2.51) 33/73, 1.03 (0.68–1.56)
XCIN3 161/165, 1.05 (0.84–1.30) 176/273, 1.58 (1.31–1.91) 132/259, 1.16 (0.94–1.43)
CIN treatments 244/275, 0.95 (0.80–1.13) 252/360, 1.72 (1.47–2.02) 188/367, 1.17 (0.98–1.39)
oCIN2 168/190, 0.95 (0.77–1.16) 238/258, 2.27 (1.90–2.70) 181/579, 0.71 (0.60–0.84)
False positive for XCIN2 334/317, 1.13 (0.97–1.31) 426/507, 2.06 (1.82–2.34) 307/1103, 0.64 (0.56–0.72)
False positive for XCIN3 383/383, 1.07 (0.93–1.23) 488/591, 2.03 (1.80–2.28) 340/1176, 0.66 (0.59–0.74)
PPV for XCIN2 39%/42%, 0.92 (0.79–1.06) 36%/41%, 0.87 (0.76–0.99) 35%/23%, 1.51 (1.29–1.76)
PPV for XCIN3 30%/30%, 0.98 (0.82–1.18) 27%/32%, 0.84 (0.71–0.98) 28%/18%, 1.55 (1.29–1.86)
45–59 years 19901/23 253 5540/16 355 13 934/27 404
XASCUS 253/352, 0.84 (0.72–0.99) 263/415, 1.87 (1.61–2.18) 180/922, 0.38 (0.33–0.45)
CIN2 14/14, 1.17 (0.56–2.45) 6/10, 1.77 (0.64–4.87) 12/17, 1.39 (0.66–2.91)
XCIN3 39/43, 1.06 (0.69–1.63) 14/63, 0.66 (0.37–1.17) 14/48, 0.57 (0.32–1.04)
CIN treatments 58/74, 0.92 (0.65–1.29) 25/86, 0.86 (0.55–1.34) 34/86, 0.78 (0.52–1.16)
oCIN2 106/190, 0.65 (0.51–0.83) 85/206, 1.22 (0.95–1.57) 110/556, 0.39 (0.32–0.48)
False positive for XCIN2 200/295, 0.79 (0.66–0.95) 243/342, 2.10 (1.78–2.47) 154/857, 0.35 (0.30–0.42)
False positive for XCIN3 214/309, 0.81 (0.68–0.96) 249/352, 2.09 (1.78–2.45) 166/874, 0.37 (0.32–0.44)
PPV for XCIN2 21%/16%, 1.29 (0.92–1.81) 8%/18%, 0.43 (0.27–0.69) 14%/7%, 2.05 (1.34–3.14)
PPV for XCIN3 15%/12%, 1.26 (0.84–1.89) 5%/15%, 0.35 (0.20–0.61) 8%/5%, 1.49 (0.84–2.65)
Abbreviations: ASCUS¼ atypical squamous cells of undetermined significance; CI¼ confidence interval; CIN¼ cervical intraepithelial neoplasia; CPH M¼Copenhagen Municipality; HC2¼
Hybrid Capture 2; Nafter¼ last phase; Nbefore¼phase 1; PPV¼positive predictive value; RP¼ relative proportion; triage¼ in case of ASCUS at ageX30 years. Bold signifies significant change
comparing the last phase (‘after’) with phase 1 (‘before’).
aCompared with manually read conventional cytology (baseline).
bNafter/Nbefore, RR (95% CI).
cNafter/Nbefore, RR (95% CI).
dNafter/Nbefore, RR (95% CI).
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Strengths and weaknesses. We included routine samples from
women targeted by the Danish screening programme. Abnormal-
ities were verified through four nation-wide registers. Abnormal
cytology was defined as any abnormality that would trigger follow-up,
either through repeated testing or a referral for colposcopy.
Histology was ascertained practically throughout the whole three-
yearly screening round, and only periods with highly complete
histological registration were included. Compared with other
studies of routine screening, the proportion of women with
histological verification of XASCUS was relatively high. We
excluded all piloting and implementation periods. Although some
remaining learning curve effects cannot be entirely dismissed
(Kirschner et al, 2006), the outcomes of our study should be
representative for a ‘normal’ use of the evaluated technologies.
As a limitation, it should be emphasised that ThinPrep data
were based on a single laboratory. This laboratory started with a
high proportion of cytological abnormalities (Rask et al, 2014),
possibly signifying a relatively high sensitivity and low specificity
for detecting high-grade CIN to begin with. In this laboratory, a
clear advantage of ThinPrep technologies was an improvement in
screening specificity.
Inferences regarding causation should be made cautiously. A
competing explanation for the observed changes could be a
changed risk of cervical lesions. This is, however, unlikely. First, the
changes in the laboratory that continuously used manually read
conventional cytology were of a substantially smaller magnitude
compared with in the laboratories with changing technologies.
Second, the laboratories served catchment areas in relatively close
geographical proximity, and no change during the study period
with a potentially differential effect on the background risk of
cervical cancer could be identified.
Our study covered a 10-year period plus 2.5-year follow-up,
during which the women’s sociodemographic characteristics and
screening histories may have changed. Ideally, these would have
been adjusted for in the analysis. The age structure changed very
little, and all analyses were age-stratified. Given Denmark’s
homogeneity, any changes in the sociodemographic factors would
affect Roskilde’s catchment area in a similar way as those of other
laboratories.
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Figure 1. Frequency of histologically confirmedXCIN2, by laboratory
and phase. Roskilde: manually read conventional cytology in all phases.
Hvidovre and Hillerød: SurePath/FocalPoint reading and liquid-based
cytology technologies. Odense: ThinPrep reading and liquid-based
cytology technologies. J, 23–29 years; &, 30–44 years; B, 45–59
years. Phases as described in Table 1. CPH M, Copenhagen
Municipality.
1 2 3 1 2 3 4 5
1a 1b 2 3 2 3 4
Hvidovre CPH M (SurePath)Roskilde
Hillerød (SurePath)Odense (ThinPrep)
1%
2%
3%
1%
2%
3%
19
98
20
00
20
02
20
04
20
06
20
08
19
98
20
00
20
02
20
04
20
06
20
08
Figure 2. Frequency of histologically confirmedoCIN2, by laboratory
and phase. Roskilde: manually read conventional cytology in all phases.
Hvidovre and Hillerød: SurePath/FocalPoint reading and liquid-based
cytology technologies. Odense: ThinPrep reading and liquid-based
cytology technologies. J, 23–29 years; &, 30–44 years, and B,
45–59 years. Phases as described in Table 1. CPH M, Copenhagen
Municipality.
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Figure 3. Frequency of false-positive tests for XCIN2 (samples with
abnormal cytology that were not followed by a histological diagnosis
of XCIN2), by laboratory and phase. Roskilde: manually read
conventional cytology in all phases. Hvidovre and Hillerød: SurePath/
FocalPoint reading and liquid-based cytology technologies. Odense:
ThinPrep reading and liquid-based cytology technologies. J, 23–29
years;&, 30–44 years;B, 45–59 years. Phases as described in Table 1.
CPH M, Copenhagen Municipality.
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In our analysis, we focused on relative changes. The
catchment area of Hvidovre to a higher extent included an
urban population, thus absolute age-specific levels of disease
detection may not have been comparable across the four
laboratories. Hence, technologies were compared strictly within
individual laboratories.
Clinical implications. The combination of screening and triage
tests should offer the highest sensitivity for high-grade CIN and an
acceptable PPV of an immediate referral to colposcopy. For
reasons of cost, logistics, and women’s discomfort, it is preferable
to perform all screening and triage tests on the same sample. A
consideration of an optimal medium for sample storage is,
therefore, going to have a role also when the switch is going to
be made from the present cytology-based screening with HPV
triage to the imminent HPV-based screening with cytology
triage. Critics have claimed that SurePath LBC medium might be
unsuitable for HPV testing (Naryshkin and Austin, 2012), and
none of the US Food and Drug Administration approvals
for HPV assays were granted for samples stored in SurePath.
Only few HPV studies evaluated SurePath samples, in particular
the Danish Horizon study evaluating APTIMA, cobas, HC2, and
CLART assays (Rebolj et al, 2013, 2014a, 2014b). The challenge
with SurePath in HPV testing is its formaldehyde content, which
induces covalent bindings between protein structures and the
HPV’s genetic material. These render the genetic material
inaccessible to enzyme-driven amplification or detection.
However, a preheating step reverses the bindings (Steinau et al,
2011). As a result, invalid HPV test results that would suggest
inaccessible genetic material tend to be infrequent (Rebolj et al,
2014a). Against this background, the improved detection of
high-grade CIN in SurePath samples observed in our study
might be relevant also for HPV-based screening with cytology
triage.
When changes are made to screening programmes, it is worth
keeping in mind the more general finding from this study, in that
replacing or adjusting a screening test can cause a shift in the
population who tests positive, is referred for further follow-up, and
finally treated. More sensitive screening methods may shift the
detection toward smaller CIN lesions with a lower potential for
progression (Schiffman and Rodriguez, 2008). In our study, an
increased detection with LBC and/or computer-assisted reading
with either brand was observed particularly at relatively young
ages, when lesions less likely progress (van Oortmarssen and
Habbema, 1991). To optimise screening recommendations with
respect to the technology, future analyses of interval cervical
cancers should determine to what extent the observed increases in
the sensitivity of cytology represented overtreatment or a reduction
in the burden of cervical cancer.
In conclusion, this study confirmed our earlier findings that
modern cytological technologies have not been neutral with respect
to the detection of cervical disease. In the Danish setting, the trends
in the sensitivity and specificity depended on the type and the
brand of the technology, and the age of the screened women. In
essence, SurePath-based technology increased the sensitivity of
cytology for high-grade cervical lesions predominantly at younger
ages, whereas ThinPrep-based technology increased the specificity
predominantly at older ages.
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APPENDIX
Table A2. Distribution of age groups by phase and laboratory
Phase 1 Phase 2 Phase 3 Phase 4 Phase 5
Roskilde
23–29 years 7350 (14%) 6346 (13%) 5572 (12%) — —
30–44 years 23 376 (43%) 21 843 (44%) 21 827 (46%) — —
45–59 years 23 253 (43%) 21 667 (43%) 19 901 (42%) — —
Total 53 797 (100%) 49 856 (100%) 47 300 (100%) — —
Mean age (s.d.) 41.8 (10.1) 42.3 (10.2) 42.2 (10.0) — —
Hvidovre (CPH M)
23–29 years 21 536 (34%) 21 537 (36%) 33 450 (35%) 13 733 (32%) 8228 (35%)
30–44 years 24 753 (40%) 21 987 (37%) 37 576 (40%) 18 348 (43%) 10 081 (42%)
45–59 years 16 355 (26%) 15 750 (27%) 23 515 (25%) 10 921 (25%) 5540 (23%)
Total 62 644 (100%) 59 274 (100%) 94 541 (100%) 43 002 (100%) 23 849 (100%)
Mean age (s.d.) 36.4 (10.4) 36.4 (10.7) 36.3 (10.6) 36.7 (10.4) 36.1 (10.4)
Hvidove (FRB M)
23–29 years — 2413 (26%) 4949 (28%) 1909 (27%) 1238 (26%)
30–44 years — 3683 (39%) 7225 (41%) 3071 (44%) 2164 (45%)
45–59 years — 3289 (35%) 5460 (31%) 2038 (29%) 1392 (29%)
Total — 9385 (100%) 17 634 (100%) 7018 (100%) 4794 (100%)
Mean age (s.d.) — 39.1 (11.0) 38.3 (11.0) 38.0 (10.8) 38.2 (10.7)
Hillerød
23–29 years — 2637 (9%) 2725 (11%) 1836 (10%) —
30–44 years — 13 342 (46%) 11 043 (45%) 8541 (46%) —
45–59 years — 12 909 (45%) 10 825 (44%) 8057 (44%) —
Total — 28 888 (100%) 24 593 (100%) 18 434 (100%) —
Mean age (s.d.) — 42.9 (9.6) 42.7 (10.0) 42.7 (9.6) —
Odense
23–29 years 14 299 (19%) 3075 (15%) 5310 (16%) — —
30–44 years 32 819 (44%) 9342 (45%) 14 370 (43%) — —
45–59 years 27 404 (37%) 8504 (41%) 13 934 (41%) — —
Total 74 522 (100%) 20 921 (100%) 33 614 (100%) — —
Mean age (s.d.) 40.1 (10.4) 41.4 (10.2) 41.5 (10.3) — —
Abbreviations: CPH M¼Copenhagen Municipality; FRB M¼ Frederiksberg Municipality.
Table A1. Completeness of 2.5-year follow-up after an XASCUS primary samplea
Phase 1 Phase 2 Phase 3 Phase 4 Phase 5
Included samples/all primary samples
Roskilde 53 979/56 769 (95%) 49 856/51 902 (96%) 47 300/48 717 (97%) — —
Hvidovre (CPH M) 62 644/73 551 (85%) 59 274/67 311 (88%) 94 541/105 483 (90%) 43 002/47 164 (91%) 23 849/25 587 (93%)
Hvidovre (FRB M) — 9385/10 540 (89%) 17 643/19 567 (90%) 7018/7639 (92%) 4794/5142 (93%)
Hillerød — 28888/29 928 (97%) 24 593/25 631 (96%) 18 434/19 178 (96%) —
Odense 74522/76 528 (97%)b 20 921/21 251 (98%) 33 614/34 066 (99%) — —
No follow-up/XASCUS
Roskilde 78/1173 (7%) 64/1251 (5%) 51/1012 (5%) — —
Hvidovre (CPH M) 111/2299 (5%) 87/2307 (4%) 343/4832 (7%) 257/2751 (9%) 120/1742 (7%)
Hvidovre (FRB M) — 9/361 (2%) 56/830 (7%) 43/420 (10%) 23/352 (7%)
Hillerød — 22/878 (3%) 26/865 (3%) 30/843 (4%) —
Odense 83/3423 (2%)c 19/536 (4%) 57/1087 (5%) — —
No histology follow-up/XASCUS
Roskilde 225/1173 (19%) 355/1251 (28%) 282/1012 (28%) — —
Hvidovre (CPH M) 612/2299 (27%) 671/2307 (29%) 1504/4832 (31%) 767/2751 (28%) 485/1742 (28%)
Hvidovre (FRB M) — 116/361 (32%) 263/830 (32%) 114/420 (27%) 88/352 (25%)
Hillerød — 320/878 (36%) 287/865 (33%) 280/843 (33%) —
Odense 1093/3423 (32%)d 108/536 (20%) 242/1087 (22%) — —
Abbreviations: ASCUS¼ atypical squamous cells of undetermined significance; CPH M¼Copenhagen Municipality; FRB M¼ Frederiksberg Municipality.
aPrimary screening samples included in the study, by laboratory and phase, women aged 23–59 years.
bPhase 1a: 29 293/30 280 (97%). Phase 1b: 45 229/46 248 (98%).
cPhase 1a: 47/1374 (3%). Phase 1b: 36/2049 (2%).
dPhase 1a: 453/1374 (33%). Phase 1b: 640/2049 (31%).
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Table A3. Laboratory with manual reading of conventional cytology throughout the study period (Roskilde)a
Phase 2 (baseline) vs phase 1 (baseline) Phase 3 (baseline) vs phase 2 (baseline)
Change in the technology None None
Same technology in both phases Conventional cytology, manual reading,
cytology triage of ASCUS
Conventional cytology, manual reading,
cytology triage of ASCUS
23–59 years 49 856/53 979 47300/49 856
XASCUS 1251/1173, 1.15 (1.07–1.25) 1012/1251, 0.85 (0.79–0.93)
CIN2 104/118, 0.95 (0.73–1.24) 85/104, 0.86 (0.65–1.15)
XCIN3 289/281, 1.11 (0.95–1.31) 271/289, 0.99 (0.84–1.17)
CIN treatments 491/482, 1.10 (0.97–1.25) 405/491, 0.87 (0.76–0.99)
oCIN2 439/471, 1.01 (0.89–1.15) 323/439, 0.78 (0.67–0.89)
False positive for XCIN2 858/774, 1.20 (1.09–1.32) 656/858, 0.81 (0.73–0.89)
False positive for XCIN3 962/892, 1.17 (1.07–1.28) 741/962, 0.81 (0.74–0.89)
PPV for XCIN2 31%/34%, 0.92 (0.82–1.04) 35%/31%, 1.12 (1.00–1.26)
PPV for XCIN3 23%/24%, 0.96 (0.84–1.11) 27%/23%, 1.16 (1.00–1.34)
23–29 years 6346/7350 5572/6346
XASCUS 254/273, 1.08 (0.91–1.27) 215/254, 0.96 (0.81–1.15)
CIN2 24/38, 0.73 (0.44–1.22) 22/24, 1.04 (0.59–1.86)
XCIN3 75/73, 1.19 (0.86–1.64) 71/75, 1.08 (0.78–1.49)
CIN treatments 119/133, 1.04 (0.81–1.32) 103/119, 0.99 (0.76–1.28)
oCIN2 77/91, 0.98 (0.72–1.33) 49/77, 0.72 (0.51–1.04)
False positive for XCIN2 155/162, 1.11 (0.89–1.38) 122/155, 0.90 (0.71–1.13)
False positive for XCIN3 179/200, 1.04 (0.85–1.26) 144/179, 0.92 (0.74–1.14)
PPV for XCIN2 39%/41%, 0.96 (0.78–1.18) 43%/39%, 1.11 (0.89–1.38)
PPV for XCIN3 30%/27%, 1.10 (0.84–1.45) 33%/30%, 1.12 (0.85–1.46)
30–44 years 21 843/23 376 21827/21 843
XASCUS 630/548, 1.23 (1.10–1.38) 544/630, 0.86 (0.77–0.97)
CIN2 72/66, 1.17 (0.84–1.63) 49/72, 0.68 (0.47–0.98)
XCIN3 180/165, 1.17 (0.95–1.44) 161/180, 0.90 (0.72–1.11)
CIN treatments 305/375, 1.19 (1.01–1.40) 244/305, 0.80 (0.68–0.95)
oCIN2 195/190, 1.10 (0.90–1.34) 168/195, 0.86 (0.70–1.06)
False positive for XCIN2 378/317, 1.28 (1.10–1.48) 334/378, 0.88 (0.76–1.02)
False positive for XCIN3 450/383, 1.26 (1.10–1.44) 383/450, 0.85 (0.74–0.97)
PPV for XCIN2 40%/42%, 0.95 (0.83–1.09) 39%/40%, 0.97 (0.84–1.11)
PPV for XCIN3 29%/30%, 0.95 (0.79–1.13) 30%/29%, 1.04 (0.87–1.24)
45–59 years 21 667/23 253 19901/21 667
XASCUS 367/352, 1.12 (0.97–1.29) 253/367, 0.75 (0.64–0.88)
CIN2 8/14, 0.61 (0.26–1.46) 14/8, 1.91 (0.80–4.54)
XCIN3 34/43, 0.85 (0.54–1.33) 39/34, 1.25 (0.79–1.98)
CIN treatments 67/74, 0.97 (0.70–1.35) 58/67, 0.94 (0.66–1.34)
oCIN2 167/190, 0.94 (0.77–1.16) 106/167, 0.69 (0.54–0.88)
False positive for XCIN2 325/295, 1.18 (1.01–1.38) 200/325, 0.67 (0.56–0.80)
False positive for XCIN3 333/309, 1.16 (0.99–1.35) 214/333, 0.70 (0.59–0.83)
PPV for XCIN2 11%/16%, 0.71 (0.49–1.02) 21%/11%, 1.83 (1.26–2.66)
PPV for XCIN3 9%/12%, 0.76 (0.50–1.16) 15%/9%, 1.66 (1.08–2.56)
Abbreviations: ASCUS¼ atypical squamous cells of undetermined significance; CIN¼ cervical intraepithelial neoplasia; PPV¼positive predictive value; triage¼ in case of ASCUS at age X30
years. Bold signifies significant change comparing the two phases.
aComparison of outcomes, by age group and phase.
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Table A4. Laboratory with SurePath cytological technology (Hvidovre/Copenhagen Municipality)a
Phase 2 vs phase 1 Phase 3 vs phase 2 Phase 4 vs phase 3 Phase 5 vs phase 4
Change in the technology FocalPoint Slide Profiler 50%
cutoff
SurePath LBC FocalPoint Slide Profiler cutoff
decreased to 25%, HC2 triage of
ASCUS
FocalPoint GS Imaging System
Same technology in both phases Conventional cytology,
cytology triage of ASCUS
FocalPoint Slide Profiler 50%
cutoff, cytology triage of
ASCUS
SurePath LBC SurePath LBC, FocalPoint Slide
Profiler 25% cutoff, HC2 triage of
ASCUS
23–59 years 59274/62644 94541/59274 43002/94541 23849/43002
XASCUS 2307/2299, 1.06 (1.00–1.12) 4832/2307, 1.31 (1.25–1.38) 2751/4832, 1.25 (1.20–1.31) 1742/2751, 1.14 (1.08–1.21)
CIN2 201/230, 0.92 (0.76–1.12) 423/201, 1.32 (1.12–1.56) 242/423, 1.26 (1.07–1.47) 162/242, 1.21 (0.99–1.47)
XCIN3 547/624, 0.93 (0.83–1.04) 1148/547, 1.32 (1.19–1.46) 641/1148, 1.23 (1.12–1.35) 394/641, 1.11 (0.98–1.26)
CIN treatments 828/857, 1.02 (0.93–1.12) 1780/828, 1.35 (1.24–1.46) 959/1780, 1.18 (1.10–1.28) 603/959, 1.13 (1.03–1.25)
oCIN2 801/722, 1.17 (1.06–1.30) 1414/801, 1.11 (1.02–1.21) 844/1414, 1.31 (1.21–1.43) 581/844, 1.24 (1.12–1.38)
False positive for XCIN2 1559/1445, 1.14 (1.06–1.22) 3261/1559, 1.31 (1.24–1.39) 1868/3261, 1.26 (1.19–1.33) 1186/1868, 1.14 (1.07–1.23)
False positive for XCIN3 1760/1675, 1.11 (1.04–1.19) 3684/1760, 1.31 (1.24–1.39) 2110/3684, 1.26 (1.20–1.33) 1348/2110, 1.15 (1.08–1.23)
PPV for XCIN2 32%/37%, 0.87 (0.81–0.94) 33%/32%, 1.00 (0.93–1.08) 32%/33%, 0.99 (0.92–1.06) 32%/32%, 0.99 (0.91–1.09)
PPV for XCIN3 24%/27%, 0.87 (0.79–0.96) 24%/24%, 1.00 (0.92–1.10) 23%/24%, 0.98 (0.90–1.07) 23%/23%, 0.97 (0.87–1.08)
23–29 years 21537/21536 33450/21537 13733/33450 8228/13733
XASCUS 1119/1020, 1.10 (1.01–1.19) 2590/1119, 1.49 (1.39–1.60) 1279/2590, 1.20 (1.13–1.28) 815/1279, 1.06 (0.98–1.16)
CIN2 120/136, 0.88 (0.69–1.13) 251/120, 1.35 (1.08–1.67) 134/251, 1.30 (1.06–1.60) 94/134, 1.17 (0.90–1.52)
XCIN3 291/288, 1.01 (0.86–1.19) 629/291, 1.39 (1.21–1.60) 316/629, 1.22 (1.07–1.40) 204/316, 1.08 (0.91–1.28)
CIN treatments 449/411, 1.09 (0.96–1.25) 996/449, 1.43 (1.28–1.59) 476/996, 1.16 (1.05–1.30) 326/476, 1.14 (1.00–1.31)
oCIN2 346/258, 1.34 (1.14–1.57) 704/346, 1.31 (1.15–1.49) 335/704, 1.16 (1.02–1.32) 258/335, 1.29 (1.10–1.51)
False positive for XCIN2 708/596, 1.19 (1.07–1.32) 1710/708, 1.56 (1.43–1.69) 829/1710, 1.18 (1.09–1.28) 517/829, 1.04 (0.94–1.16)
False positive for XCIN3 828/732, 1.13 (1.03–1.25) 1961/828, 1.52 (1.41–1.65) 963/1961, 1.20 (1.11–1.29) 611/963, 1.06 (0.96–1.17)
PPV for XCIN2 37%/42%, 0.88 (0.79–0.98) 34%/37%, 0.93 (0.84–1.02) 35%/34%, 1.04 (0.94–1.14) 37%/35%, 1.04 (0.92–1.17)
PPV for XCIN3 26%/28%, 0.92 (0.80–1.06) 24%/26%, 0.93 (0.83–1.05) 25%/24%, 1.02 (0.90–1.14) 25%/25%, 1.01 (0.87–1.18)
30–44 years 21987/24753 37576/21987 18348/37576 10081/18348
XASCUS 764/864, 1.00 (0.90–1.10) 1690/764, 1.29 (1.19–1.41) 1035/1690, 1.25 (1.16–1.35) 664/1035, 1.17 (1.06–1.28)
CIN2 63/84, 0.84 (0.61–1.17) 154/63, 1.43 (1.07–1.92) 98/154, 1.30 (1.01–1.68) 62/98, 1.15 (0.84–1.58)
XCIN3 217/273, 0.89 (0.75–1.07) 475/217, 1.28 (1.09–1.50) 291/475, 1.25 (1.09–1.45) 176/291, 1.10 (0.91–1.33)
CIN treatments 308/360, 0.96 (0.83–1.12) 702/308, 1.33 (1.17–1.52) 430/702, 1.25 (1.11–1.41) 252/430, 1.07 (0.91–1.24)
oCIN2 245/258, 1.07 (0.90–1.27) 451/245, 1.08 (0.92–1.26) 361/451, 1.64 (1.43–1.88) 238/361, 1.20 (1.02–1.41)
False positive for XCIN2 484/507, 1.07 (0.95–1.22) 1061/484, 1.28 (1.15–1.43) 646/1061, 1.25 (1.13–1.37) 426/646, 1.20 (1.06–1.35)
False positive for XCIN3 547/591, 1.04 (0.93–1.17) 1215/547, 1.30 (1.18–1.44) 744/1215, 1.25 (1.15–1.37) 488/744, 1.19 (1.07–1.33)
PPV for XCIN2 37%/41%, 0.89 (0.78–1.00) 37%/37%, 1.02 (0.91–1.14) 38%/37%, 1.01 (0.91–1.12) 36%/38%, 0.95 (0.84–1.08)
PPV for XCIN3 28%/32%, 0.90 (0.77–1.04) 28%/28%, 0.99 (0.86–1.13) 28%/28%, 1.00 (0.88–1.13) 27%/28%, 0.94 (0.80–1.11)
45–59 years 15750/16355 23515/15750 10921/23515 5540/10921
XASCUS 424/415, 1.06 (0.93–1.21) 552/424, 0.87 (0.77–0.99) 437/552, 1.70 (1.51–1.93) 263/437, 1.19 (1.02–1.38)
CIN2 18/10, 1.87 (0.86–4.05) 18/18, 0.67 (0.35–1.29) 10/18, 1.20 (0.55–2.59) 6/10, 1.18 (0.43–3.25)
XCIN3 39/63, 0.64 (0.43–0.96) 44/39, 0.76 (0.49–1.16) 34/44, 1.66 (1.06–2.60) 14/34, 0.81 (0.44–1.51)
CIN treatments 71/86, 0.86 (0.63–1.17) 82/71, 0.77 (0.56–1.06) 53/82, 1.39 (0.99–1.96) 25/53, 0.93 (0.58–1.49)
oCIN2 210/206, 1.06 (0.87–1.28) 259/210, 0.83 (0.69–0.99) 148/259, 1.23 (1.01–1.50) 85/148, 1.13 (0.87–1.48)
False positive for XCIN2 367/342, 1.11 (0.96–1.29) 490/367, 0.89 (0.78–1.02) 393/490, 1.73 (1.52–1.97) 243/393, 1.22 (1.04–1.43)
False positive for XCIN3 385/352, 1.14 (0.98–1.31) 508/385, 0.88 (0.78–1.01) 403/508, 1.71 (1.50–1.94) 249/403, 1.22 (1.04–1.42)
PPV for XCIN2 13%/18%, 0.76 (0.56–1.05) 11%/13%, 0.84 (0.60–1.17) 10%/11%, 0.90 (0.62–1.29) 8%/10%, 0.76 (0.46–1.25)
PPV for XCIN3 9%/15%, 0.61 (0.42–0.88) 8%/9%, 0.87 (0.57–1.31) 8%/8%, 0.98 (0.64–1.50) 5%/8%, 0.68 (0.37–1.25)
Abbreviations: ASCUS¼ atypical squamous cells of undetermined significance; CIN¼ cervical intraepithelial neoplasia; HC2¼Hybrid Capture 2; PPV¼positive predictive value; triage¼ in case
of ASCUS at age X30 years. Bold signifies significant change comparing the two phases.
aComparison of outcomes, by age group and phase.
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Table A5. Laboratory with SurePath cytological technology (Hvidovre/Frederiksberg Municipality)a
Phase 3 vs phase 2 Phase 4 vs phase 3 Phase 5 vs phase 4
Change in the technology SurePath LBC FocalPoint Slide Profiler cutoff decreased
to 25%, HC2 triage of ASCUS
FocalPoint GS Imaging System
Same technology in both phases FocalPoint Slide Profiler 50%
cutoff, cytology triage of ASCUS
SurePath LBC SurePath LBC, FocalPoint Slide Profiler
25% cutoff, HC2 triage of ASCUS
23–59 years 17634/9385 7018/17 634 4794/7018
XASCUS 830/361, 1.22 (1.08–1.38) 420/830, 1.27 (1.13–1.43) 352/420, 1.23 (1.07–1.41)
CIN2 77/26, 1.58 (1.01–2.46) 51/77, 1.66 (1.17–2.37) 39/51, 1.12 (0.74–1.70)
XCIN3 195/97, 1.07 (0.84–1.36) 107/195, 1.38 (1.09–1.74) 80/107, 1.09 (0.82–1.46)
CIN treatments 304/134, 1.21 (0.99–1.48) 169/304, 1.40 (1.16–1.68) 140/169, 1.21 (0.97–1.51)
oCIN2 239/113, 1.13 (0.90–1.41) 105/239, 1.10 (0.88–1.39) 122/105, 1.70 (1.31–2.20)
False positive for XCIN2 558/238, 1.25 (1.07–1.45) 262/558, 1.18 (1.02–1.36) 233/262, 1.30 (1.10–1.55)
False positive for XCIN3 635/264, 1.28 (1.11–1.47) 313/635, 1.24 (1.08–1.41) 272/313, 1.27 (1.09–1.49)
PPV for XCIN2 33%/34%, 0.96 (0.81–1.14) 38%/33%, 1.15 (0.98–1.34) 34%/38%, 0.90 (0.74–1.09)
PPV for CIN3 23%/27%, 0.87 (0.71–1.08) 25%/23%, 1.08 (0.88–1.33) 23%/25%, 0.89 (0.69–1.15)
23–29 years 4949/2413 1909/4949 1238/1909
XASCUS 367/133, 1.35 (1.11–1.63) 174/367, 1.23 (1.03–1.46) 135/174, 1.20 (0.97–1.48)
CIN2 45/19, 1.15 (0.68–1.97) 21/45, 1.21 (0.72–2.03) 24/21, 1.76 (0.99–3.15)
XCIN3 97/36, 1.31 (0.90–1.92) 56/97, 1.50 (1.08–2.07) 37/56, 1.02 (0.68–1.53)
CIN treatments 156/55, 1.38 (1.02–1.87) 81/156, 1.35 (1.03–1.75) 66/81, 1.26 (0.92–1.73)
oCIN2 92/30, 1.50 (0.99–2.25) 34/92, 0.96 (0.65–1.41) 38/34, 1.72 (1.09–2.72)
False positive for XCIN2 225/78, 1.41 (1.09–1.81) 97/225, 1.12 (0.89–1.41) 74/97, 1.18 (0.88–1.58)
False positive for XCIN3 270/97, 1.36 (1.08–1.70) 118/270, 1.13 (0.92–1.40) 98/118, 1.28 (0.99–1.66)
PPV for XCIN2 39%/41%, 0.94 (0.74–1.19) 44%/39%, 1.14 (0.93–1.41) 45%/44%, 1.02 (0.80–1.31)
PPV for CIN3 26%/27%, 0.98 (0.70–1.35) 32%/26%, 1.22 (0.92–1.60) 27%/32%, 0.85 (0.60–1.21)
30–44 years 7225/3683 3071/7225 2164/3071
XASCUS 334/136, 1.25 (1.03–1.52) 176/334, 1.24 (1.04–1.48) 151/176, 1.22 (0.99–1.50)
CIN2 31/5, 3.16 (1.23–8.12) 28/31, 2.12 (1.28–3.54) 13/28, 0.66 (0.34–1.27)
XCIN3 82/44, 0.95 (0.66–1.37) 50/82, 1.43 (1.01–2.03) 42/50, 1.19 (0.79–1.79)
CIN treatments 129/55, 1.20 (0.87–1.64) 85/129, 1.55 (1.18–2.03) 67/85, 1.12 (0.82–1.53)
oCIN2 94/42, 1.14 (0.79–1.64) 49/94, 1.23 (0.87–1.73) 60/49, 1.74 (1.20–2.52)
False positive for XCIN2 221/87, 1.29 (1.01–1.65) 98/221, 1.04 (0.83–1.32) 96/98, 1.39 (1.05–1.83)
False positive for XCIN3 252/92, 1.40 (1.10–1.77) 126/252, 1.18 (0.95–1.45) 109/126, 1.23 (0.96–1.58)
PPV for XCIN2 34%/36%, 0.94 (0.72–1.23) 44%/34%, 1.31 (1.05–1.64) 36%/44%, 0.82 (0.63–1.07)
PPV for CIN3 25%/32%, 0.76 (0.56–1.03) 28%/25%, 1.16 (0.86–1.56) 28%/28%, 0.98 (0.69–1.39)
45–59 years 5460/3289 2038/5460 1392/2038
XASCUS 129/92, 0.84 (0.65–1.10) 70/129, 1.45 (1.09–1.94) 66/70, 1.38 (0.99–1.92)
CIN2 1/2, 0.30 (0.03–3.32) 2/1, 5.36 (0.49–59.06) 2/2, 1.46 (0.21–10.38)
XCIN3 16/17, 0.57 (0.29–1.12) 1/16, 0.17 (0.02–1.26) 1/1, 1.46 (0.09–23.39)
CIN treatments 19/24, 0.48 (0.26–0.87) 3/19, 0.42 (0.13–1.43) 7/3, 3.42 (0.88–13.19)
oCIN2 53/41, 0.78 (0.52–1.17) 22/53, 1.11 (0.68–1.82) 24/22, 1.60 (0.90–2.84)
False positive for XCIN2 112/73, 0.92 (0.69–1.24) 67/112, 1.60 (1.19–2.16) 63/67, 1.38 (0.98–1.93)
False positive for XCIN3 113/75, 0.91 (0.68–1.21) 69/113, 1.64 (1.22–2.20) 65/69, 1.38 (0.99–1.92)
PPV for XCIN2 13%/21%, 0.64 (0.35–1.16) 4%/13%, 0.33 (0.10–1.07) 5%/4%, 1.06 (0.22–5.07)
PPV for CIN3 12%/18%, 0.67 (0.36–1.26) 1%/12%, 0.12 (0.02–0.85) 2%/1%, 1.06 (0.07–16.61)
Abbreviations: ASCUS¼ atypical squamous cells of undetermined significance; CIN¼ cervical intraepithelial neoplasia; HC2¼Hybrid Capture 2; PPV¼positive predictive value; triage¼ in case
of ASCUS at age X30 years. Bold signifies significant change comparing the two phases.
aComparison of outcomes, by age group and phase.
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Table A6. Laboratory with SurePath cytological technology (Hillerød)a
Phase 3 vs phase 2 Phase 4 vs phase 3
Change in the technology SurePath LBC, FocalPoint Slide Profiler cutoff
decreased to 25%
FocalPoint GS Imaging System
Same technology in both phases Cytology triage of ASCUS SurePath LBC, Focal Point Slide Profiler 25% cutoff, cytology
triage of ASCUS
23–59 years 24 593/28 888 18 434/24 593
XASCUS 865/878, 1.16 (1.06–1.27) 843/865, 1.30 (1.18–1.43)
CIN2 71/67, 1.24 (0.89–1.74) 77/71, 1.45 (1.05–2.00)
XCIN3 183/151, 1.42 (1.15–1.76) 181/183, 1.32 (1.08–1.62)
CIN treatments 291/281, 1.22 (1.03–1.43) 280/291, 1.28 (1.09–1.51)
oCIN2 298/318, 1.10 (0.94–1.29) 275/298, 1.23 (1.05–1.45)
False positive for XCIN2 611/660, 1.09 (0.98–1.21) 585/611, 1.28 (1.14–1.43)
False positive for XCIN3 682/727, 1.10 (0.99–1.22) 662/682, 1.29 (1.17–1.44)
PPV for XCIN2 29%/25%, 1.18 (1.01–1.38) 31%/29%, 1.04 (0.90–1.20)
PPV for XCIN3 21%/17%, 1.23 (1.01–1.49) 21%/21%, 1.01 (0.85–1.22)
23–29 years 2725/2637 1836/2725
XASCUS 163/110, 1.43 (1.13–1.82) 151/163, 1.37 (1.11–1.70)
CIN2 18/15, 1.16 (0.59–2.30) 27/18, 2.23 (1.23–4.03)
XCIN3 49/31, 1.53 (0.98–2.39) 51/49, 1.54 (1.05–2.28)
CIN treatments 71/52, 1.32 (0.93–1.88) 80/71, 1.67 (1.22–2.29)
oCIN2 43/25, 1.66 (1.02–2.72) 32/43, 1.10 (0.70–1.74)
False positive for XCIN2 96/64, 1.45 (1.06–1.98) 73/96, 1.13 (0.84–1.52)
False positive for XCIN3 114/79, 1.40 (1.05–1.85) 100/114, 1.30 (1.00–1.69)
PPV for XCIN2 41%/42%, 0.98 (0.74–1.31) 52%/41%, 1.26 (0.99–1.60)
PPV for XCIN3 30%/28%, 1.07 (0.73–1.56) 34%/30%, 1.12 (0.81–1.55)
30–44 years 11 043/13 342 8541/11 043
XASCUS 486/438, 1.34 (1.18–1.52) 462/486, 1.23 (1.09–1.39)
CIN2 42/41, 1.24 (0.81–1.90) 42/42, 1.29 (0.84–1.98)
XCIN3 119/96, 1.50 (1.15–1.96) 110/119, 1.20 (0.92–1.55)
CIN treatments 183/166, 1.33 (1.08–1.64) 163/183, 1.15 (0.93–1.42)
oCIN2 149/141, 1.28 (1.02–1.61) 131/149, 1.14 (0.90–1.44)
False positive for XCIN2 325/301, 1.30 (1.12–1.52) 310/325, 1.23 (1.06–1.44)
False positive for XCIN3 367/342, 1.30 (1.12–1.50) 352/367, 1.24 (1.07–1.43)
PPV for XCIN2 33%/31%, 1.06 (0.88–1.28) 33%/33%, 0.99 (0.83–1.19)
PPV for XCIN3 24%/22%, 1.12 (0.88–1.41) 24%/24%, 0.97 (0.78–1.22)
45–59 years 10 825/12 909 8057/10 825
XASCUS 216/330, 0.78 (0.66–0.92) 230/216, 1.43 (1.19–1.72)
CIN2 11/11, 1.19 (0.52–2.75) 8/11, 0.98 (0.39–2.43)
XCIN3 15/24, 0.75 (0.39–1.42) 20/15, 1.79 (0.92–3.50)
CIN treatments 37/63, 0.70 (0.47–1.05) 37/37, 1.34 (0.85–2.12)
oCIN2 106/152, 0.83 (0.65–1.06) 112/106, 1.42 (1.09–1.85)
False positive for XCIN2 190/295, 0.77 (0.64–0.92) 202/190, 1.43 (1.17–1.74)
False positive for XCIN3 201/306, 0.78 (0.66–0.93) 210/201, 1.40 (1.16–1.70)
PPV for XCIN2 12%/11%, 1.13 (0.70–1.83) 12%/12%, 1.01 (0.61–1.67)
PPV for XCIN3 7%/7%, 0.95 (0.51–1.78) 9%/7%. 1.25 (0.66–2.38)
Abbreviations: ASCUS¼ atypical squamous cells of undetermined significance; CIN¼ cervical intraepithelial neoplasia; LBC¼ liquid-based cytology; PPV¼positive predictive value; triage¼ in
case of ASCUS at age X30 years. Bold signifies significant change comparing the two phases.
aComparison of outcomes, by age group and phase.
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Table A7. Laboratory with ThinPrep cytological technology (Odense)a
Phase 2 vs phase 1 Phase 3 vs phase 2
Change in the technology ThinPrep LBC ThinPrep Imaging System
Same technology in both phases Manual reading, cytology triage of ASCUS ThinPrep LBC, cytology triage of ASCUS
23–59 years 20 921/74 522 33614/20 921
XASCUS 536/3423, 0.56 (0.51–0.61) 1087/536, 1.26 (1.14–1.40)
CIN2 31/183, 0.60 (0.41–0.88) 106/31, 2.13 (1.43–3.17)
XCIN3 163/557, 1.04 (0.88–1.24) 249/163, 0.95 (0.78–1.16)
CIN treatments 219/826, 0.94 (0.81–1.10) 389/219, 1.11 (0.94–1.30)
oCIN2 215/1507, 0.51 (0.44–0.59) 433/215, 1.25 (1.07–1.47)
False positive for XCIN2 342/2683, 0.45 (0.41–0.51) 732/342, 1.33 (1.17–1.51)
False positive for XCIN3 373/2866, 0.46 (0.42–0.52) 838/373, 1.40 (1.24–1.58)
PPV for XCIN2 36%/22%, 1.67 (1.47–1.91) 33%/36%, 0.90 (0.78–1.04)
PPV for XCIN3 30%/16%, 1.87 (1.61–2.17) 23%/30%, 0.75 (0.64–0.89)
23–29 years 3075/14 299 5310/3075
XASCUS 208/1066, 0.91 (0.79–1.05) 435/208, 1.21 (1.03–1.42)
CIN2 15/93, 0.75 (0.44–1.29) 61/15, 2.35 (1.34–4.14)
XCIN3 65/250, 1.21 (0.92–1.58) 103/65, 0.92 (0.67–1.25)
CIN treatments 89/373, 1.11 (0.88–1.39) 167/89, 1.09 (0.84–1.40)
oCIN2 63/372, 0.79 (0.60–1.03) 142/63, 1.31 (0.97–1.75)
False positive for XCIN2 128/723, 0.82 (0.68–0.99) 271/128, 1.23 (1.00–1.51)
False positive for XCIN3 143/816, 0.81 (0.69–0.97) 332/143, 1.34 (1.11–1.63)
PPV for XCIN2 38%/32%, 1.20 (0.99–1.45) 38%/38%, 0.98 (0.79–1.21)
PPV for XCIN3 31%/23%, 1.33 (1.06–1.68) 24%/31%, 0.76 (0.58–0.99)
30–44 years 9342/32 819 14370/9342
XASCUS 242/1435, 0.59 (0.52–0.68) 472/242, 1.27 (1.09–1.48)
CIN2 13/73, 0.63 (0.35–1.13) 33/13, 1.65 (0.87–3.13)
XCIN3 80/259, 1.09 (0.85–1.39) 132/80, 1.07 (0.81–1.41)
CIN treatments 102/367, 0.98 (0.78–1.21) 188/102, 1.20 (0.94–1.52)
oCIN2 98/579, 0.59 (0.48–0.74) 181/98, 1.20 (0.94–1.53)
False positive for XCIN2 149/1103, 0.47 (0.40–0.56) 307/149, 1.34 (1.10–1.63)
False positive for XCIN3 162/1176, 0.48 (0.41–0.57) 340/162, 1.36 (1.13–1.64)
PPV for XCIN2 38%/23%, 1.66 (1.38–2.00) 35%/38%, 0.91 (0.74–1.11)
PPV for XCIN3 33%/18%, 1.83 (1.48–2.26) 28%/33%, 0.85 (0.67–1.07)
45–59 years 8504/27 404 13934/8504
XASCUS 86/922, 0.30 (0.24–0.37) 180/86, 1.28 (0.99–1.65)
CIN2 3/17, 0.57 (0.17–1.94) 12/3, 2.44 (0.69–8.65)
XCIN3 18/48, 1.21 (0.70–2.08) 14/18, 0.47 (0.24–0.95)
CIN treatments 28/86, 1.05 (0.69–1.61) 34/28, 0.74 (0.45–1.22)
oCIN2 54/556, 0.31 (0.24–0.41) 110/54, 1.24 (0.90–1.72)
False positive for XCIN2 65/857, 0.24 (0.19–0.31) 154/65, 1.45 (1.08–1.93)
False positive for XCIN3 68/874, 0.25 (0.20–0.32) 166/68, 1.49 (1.12–1.97)
PPV for XCIN2 24%/7%, 3.46 (2.23–5.38) 14%/24%, 0.59 (0.35–0.99)
PPV for XCIN3 21%/5%, 4.02 (2.45–6.59) 8%/21%, 0.37 (0.19–0.71)
Abbreviations: ASCUS¼ atypical squamous cells of undetermined significance; CIN¼ cervical intraepithelial neoplasia; LBC¼ liquid-based cytology; PPV¼positive predictive value; triage¼ in
case of ASCUS at age X30 years. Bold signifies significant change comparing the two phases.
aComparison of outcomes, by age group and phase.
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